Cited 0 times in
Dual antiplatelet therapy after percutaneous coronary intervention for left main coronary artery disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김인수 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 이승준 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 홍성진 | - |
dc.date.accessioned | 2024-05-30T07:09:48Z | - |
dc.date.available | 2024-05-30T07:09:48Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 0300-8932 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/199612 | - |
dc.description.abstract | Introduction and objectives: There are scarce data on the optimal duration and prognostic impact of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with second-generation drug-eluting stents for left main coronary artery (LMCA) disease. The aim of this study was to investigate the practice pattern and long-term prognostic effect of DAPT duration in patients undergoing PCI with second-generation drug-eluting stents for LMCA disease. Methods: Using individual patient-level data from the IRIS-MAIN and KOMATE registries, 1827 patients undergoing PCI with second-generation drug-eluting stents for LMCA disease with valid information on DAPT duration were included. The efficacy outcome was major adverse cardiovascular events (MACE, a composite of cardiac death, myocardial infarction, and stent thrombosis) and the safety outcome was TIMI major bleeding. Results: DAPT duration was < 6 months (n = 273), 6 to 12 months (n = 477), 12 to 24 months (n = 637), and >= 24 months (n = 440). The median follow-up duration was 3.9 [interquartile range, 3.01-5.00] years. Prolonged DAPT duration was associated with lower incidences of MACE. In multigroup propensity score analysis, adjusted HR for MACE were significantly higher for DAPT < 6 months and DAPT 6 to 12 months than for DAPT 12 to 24 months (HR, 4.51; 95%CI, 2.96-6.88 and HR 1.92; 95%CI, 1.23-3.00). There was no difference in HR for major bleeding among the assessed groups. Conclusions: DAPT duration following PCI for LMCA disease is highly variable. Although the duration of DAPT should be considered in the context of the clinical situation of each patient, < 12 months of DAPT was associated with higher incidence of MACE. Registration identifiers: NCT01341327; NCT03908463. (c) 2022 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | Spanish, English(Summary) | - |
dc.publisher | Elsevier España | - |
dc.relation.isPartOf | REVISTA ESPANOLA DE CARDIOLOGIA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Coronary Artery Disease* / complications | - |
dc.subject.MESH | Coronary Artery Disease* / surgery | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Hemorrhage / chemically induced | - |
dc.subject.MESH | Hemorrhage / complications | - |
dc.subject.MESH | Hemorrhage / epidemiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Myocardial Infarction* / etiology | - |
dc.subject.MESH | Percutaneous Coronary Intervention* / adverse effects | - |
dc.subject.MESH | Platelet Aggregation Inhibitors / therapeutic use | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Dual antiplatelet therapy after percutaneous coronary intervention for left main coronary artery disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sungsoo Cho | - |
dc.contributor.googleauthor | Do-Yoon Kang | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Duk-Woo Park | - |
dc.contributor.googleauthor | In-Soo Kim | - |
dc.contributor.googleauthor | Tae Soo Kang | - |
dc.contributor.googleauthor | Jung-Min Ahn | - |
dc.contributor.googleauthor | Pil Hyung Lee | - |
dc.contributor.googleauthor | Soo-Jin Kang | - |
dc.contributor.googleauthor | Seung-Whan Lee | - |
dc.contributor.googleauthor | Young-Hak Kim | - |
dc.contributor.googleauthor | Cheol Whan Lee | - |
dc.contributor.googleauthor | Seong-Wook Park | - |
dc.contributor.googleauthor | Seung-Jun Lee | - |
dc.contributor.googleauthor | Sung-Jin Hong | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Seung-Jung Park | - |
dc.identifier.doi | 10.1016/j.recesp.2022.07.006 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00840 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A02269 | - |
dc.contributor.localId | A02927 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A04403 | - |
dc.relation.journalcode | J02623 | - |
dc.identifier.eissn | 1579-2242 | - |
dc.identifier.pmid | 35907438 | - |
dc.identifier.url | https://www.revespcardiol.org/en-linkresolver-dual-antiplatelet-therapy-after-percutaneous-S1885585722002031 | - |
dc.subject.keyword | Drug-eluting stents | - |
dc.subject.keyword | Dual antiplatelet therapy | - |
dc.subject.keyword | Enfermedad del tronco coronario izquierdo | - |
dc.subject.keyword | Left main coronary artery disease | - |
dc.subject.keyword | Stents farmacoactivos | - |
dc.subject.keyword | Tratamiento antiagregante plaquetario doble | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 김인수 | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 안철민 | - |
dc.contributor.affiliatedAuthor | 이승준 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 홍성진 | - |
dc.citation.volume | 76 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 245 | - |
dc.citation.endPage | 252 | - |
dc.identifier.bibliographicCitation | REVISTA ESPANOLA DE CARDIOLOGIA, Vol.76(4) : 245-252, 2023-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.